Revvity, Inc. (NYSE: RVTY) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $17.2B. The Maz Rating grades it against the other companies in its sector.
Revvity, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $154.39, Revvity, Inc. trades at 68.3x trailing earnings, 5.9x sales and 2.4x book value, with an EV/EBITDA of 24.6. Over the last twelve months it generated about $2.9B of revenue and $252M of net income. It runs a gross margin of 53.1%, an operating margin of 12.6% and a net margin of 8.6%. It shows return on equity of 3.5%, return on invested capital of 3.1% and a free cash flow yield of 3.4%. On the balance sheet: a debt-to-equity ratio of 0.38 and a current ratio of 2.65. Over the past 52 weeks the share price ranged from $81.22 to $171.74, with a beta of 1.08.
Revvity, Inc. pays a dividend yielding 0.18%, with 12% of earnings paid out. Its Maz Dividend Score is 3.43 out of 5, ranked against the other dividend payers in its sector (Safety 4.50, Growth 1.83, Yield 1.10, Consistency 3.75).
30 Wall Street analyst ratings cover the stock: 15 Buy and 15 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of October 2026, Revvity, Inc. (RVTY) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 16.3% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.67% / 30% · Interest income / Revenue 0.49% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 16.3% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.66% / 33% · Receivables / Mkt Cap (36m) 4.25% / 49% · Interest income / Revenue 0.49% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 16.3% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.66% / 33.33% · Receivables / Mkt Cap (24m) 4.25% / 33.33% · Interest income / Revenue 0.49% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 26.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 7.12% / 33.33% · Receivables / Avg Assets (4Q) 5.94% / 33.33% · Interest income / Revenue 0.49% / 5% | Pass |
| FTSE | Debt / Total Assets 22.9% / 33.33% · (Cash+ST Inv) / Total Assets 5.16% / 33.33% · (Cash+Recv) / Total Assets 11.1% / 33.33% · Interest income / Revenue 0.49% / 5% | Pass |
Yes. As of October 2026, Revvity, Inc. (RVTY) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Revvity, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.49% of each dividend: Revvity, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated October 4, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.